The Current Evidence on Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
10.5090/kjtcs.2020.53.4.160
- Author:
Dongryul OH
1
;
Jong Hoon KIM
Author Information
1. Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea
- Publication Type:Collective of current Review, Lecture
- From:The Korean Journal of Thoracic and Cardiovascular Surgery
2020;53(4):160-167
- CountryRepublic of Korea
-
Abstract:
Surgical resection is the mainstay of treatment for locally advanced esophageal cancer.Neoadjuvant therapy is recommended to improve survival, based on the results of severalrandomized trials and meta-analyses. However, controversy remains regarding howto combine surgery, radiotherapy, and chemotherapy. Moreover, in East Asia, the predominanthistological type is esophageal squamous cell carcinoma, which has a differentepidemiology and tumor biology from esophageal or gastroesophageal junctional adenocarcinoma.As such, the management of esophageal cancer in East Asia seems to bedifferent from that in Western countries. Thus, this article reviews the current evidence onneoadjuvant therapy and considers the optimal combinations and ongoing strategies ofmultimodal therapy for esophageal squamous cell carcinoma.
